Annovera™ Drug-Drug Interaction Study
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 70
Summary
- Conditions
- Contraception
- Women
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: Two cohort, open label, randomized, two period (Cycle 1 and Cycle 2) crossover study. Subjects may only participate in one randomized sequence of one cohort. Subjects will be assigned to either Cohort 1 (itraconazole) or Cohort 2 (rifampin). Once assigned, a subject will then be randomized to a Sequence Group within the cohort. There will be at least a 4-week washout between Treatment Cycle 1 and Cycle 2.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 35 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04290390
- Collaborators
- Not Provided
- Investigators
- Study Chair: Sebastian Mirkin, MD TherapeuticsMD
Get Well Soon